{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:27Z","timestamp":1762842207463,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2020.100295","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T10:50:42Z","timestamp":1608979842000},"page":"100295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Heart rate variability and vibration perception threshold to assess chemotherapy-induced neuropathy in women with breast cancer \u2013 a systematic review"],"prefix":"10.1016","volume":"26","author":[{"given":"Simone Diedrichsen","family":"Marstrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Buch-Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Thorbj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ctarc.2020.100295_bib0001","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2020.100295_bib0002","article-title":"NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries [Webpage]. Association of the Nordic Cancer Registries","author":"Danckert B","year":"2009","journal-title":"Danish Cancer Society"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100295_bib0003","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100295_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.14423\/SMJ.0000000000000701","article-title":"Breast cancer survivorship: patient characteristics and plans for high-quality care","volume":"110","author":"Loftus","year":"2017","journal-title":"South Med J"},{"issue":"9","key":"10.1016\/j.ctarc.2020.100295_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","article-title":"Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis","volume":"1","author":"Fujii","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9814","key":"10.1016\/j.ctarc.2020.100295_bib0006","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100295_bib0007","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J. Clin. Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.ctarc.2020.100295_bib0009","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/annonc\/mdu186","article-title":"Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression","author":"Nitz","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100295_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx140","article-title":"Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review","volume":"110","author":"Rivera","year":"2018","journal-title":"J. Natl. Cancer Inst"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100295_bib0011","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","article-title":"Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer","author":"Speck","year":"2013","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100295_bib0012","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0016","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1212\/WNL.46.1.108","article-title":"Peripheral neuropathy secondary to docetaxel (Taxotere)","volume":"46","author":"New","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100295_bib0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s004010051132","article-title":"Docetaxel neuropathy: a distal axonopathy","volume":"98","author":"Fazio","year":"1999","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0019","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1212\/WNL.46.1.104","article-title":"Peripheral neurotoxicity induced by docetaxel","volume":"46","author":"Hilkens","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","article-title":"Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study","volume":"144","author":"Attal","year":"2009","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100295_bib0021","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpainsymman.2016.12.342","article-title":"Chemotherapy-Induced Neuropathy in Cancer Survivors","volume":"54","author":"Miaskowski","year":"2017","journal-title":"J. Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0022","first-page":"e133","article-title":"Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study","volume":"15","author":"Kokotis","year":"2016","journal-title":"Clin. Colorectal. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100295_bib0023","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctarc.2020.100295_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psyneuen.2016.02.018","article-title":"Heart rate variability measure in breast cancer patients and survivors: a systematic review","volume":"68","author":"Arab","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(02)00057-8","article-title":"Functional assessment of heart rate variability: physiological basis and practical applications","volume":"84","author":"Pumprla","year":"2002","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100295_bib0027","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1985.3.6.818","article-title":"A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer","volume":"3","author":"Jain","year":"1985","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-007-9438-8","article-title":"Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings","volume":"86","author":"Augusto","year":"2008","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1005805907311","article-title":"Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing","volume":"35","author":"Forsyth","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctarc.2020.100295_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918816462","article-title":"Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors","volume":"14","author":"Kober","year":"2018","journal-title":"Mol Pain"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100295_bib0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mus.21874","article-title":"Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy","volume":"43","author":"Park","year":"2011","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100295_bib0032","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","article-title":"Paclitaxel (Taxol) induces cumulative mild neurotoxicity","volume":"30a","author":"van Gerven","year":"1994","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100295_bib0033","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1078-0432.CCR-0772-03","article-title":"Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine","volume":"10","author":"Openshaw","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0034","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00001813-200204000-00012","article-title":"Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines","volume":"13","author":"Ekholm","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00001813-200301000-00010","article-title":"Docetaxel with epirubicin\u2013investigations on cardiac safety","volume":"14","author":"Salminen","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100295_bib0036","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5603\/KP.2018.0098","article-title":"Heart rate variability during and after chemotherapy with anthracycline in patients with breast cancer","volume":"76","author":"Stachowiak","year":"2018","journal-title":"Kardiol Pol"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0037","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/hrt.81.4.419","article-title":"Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables","volume":"81","author":"Tjeerdsma","year":"1999","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100295_bib0038","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.2001.19.10.2746","article-title":"Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients","volume":"19","author":"Meinardi","year":"2001","journal-title":"J Clin Oncol"},{"issue":"44","key":"10.1016\/j.ctarc.2020.100295_bib0039","doi-asserted-by":"crossref","first-page":"e5228","DOI":"10.1097\/MD.0000000000005228","article-title":"Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctarc.2020.100295_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05416-4","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing","author":"Zhi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100295_bib0042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1099800414568100","article-title":"Heart rate variability in breast cancer survivors after the first year of treatments: a case-controlled study","volume":"18","author":"Caro-Moran","year":"2016","journal-title":"Biol Res Nurs"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100295_bib0043","first-page":"555","article-title":"Changes in cardiac autonomic modulation in women with breast cancer using aromatase inhibitors and the relation with biochemical variables","volume":"112","author":"Gonzaga","year":"2019","journal-title":"Arq Bras, Cardiol"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0044","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s11764-015-0445-z","article-title":"Evidence of altered autonomic cardiac regulation in breast cancer survivors","volume":"9","author":"Vigo","year":"2015","journal-title":"J Cancer Surviv"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195166","article-title":"Heart rate variability in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Benichou","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0046","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/PSY.0000000000000167","article-title":"Higher vagal activity as related to survival in patients with advanced breast cancer: an analysis of autonomic dysregulation","volume":"77","author":"Giese-Davis","year":"2015","journal-title":"Psychosom Med"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0047","first-page":"299","article-title":"Heart rate variability and myocardial infarction: systematic literature review and metanalysis","volume":"13","author":"Buccelletti","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100295_bib0048","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/01616412.2018.1438225","article-title":"Is neuropathic pain associated with cardiac sympathovagal activity changes in patients with breast cancer?","volume":"40","author":"Yesil","year":"2018","journal-title":"Neurol Res"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100295_bib0049","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.ctarc.2020.100295_bib0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ctarc.2020.100295_bib0051","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/IJWH.S69907","article-title":"Clinical utilities of aromatase inhibitors in breast cancer","volume":"7","author":"Chumsri","year":"2015","journal-title":"Int J Womens Health"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100295_bib0052","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s00125-017-4245-z","article-title":"Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study","volume":"60","author":"Azmi","year":"2017","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.ctarc.2020.100295_bib0053","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.2337\/dc18-1236","article-title":"Atherosclerosis and Microvascular Complications: results From the Canadian Study of Longevity in Type 1","volume":"41","author":"Lovshin","year":"2018","journal-title":"Diabetes. Diabetes Care."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:51Z","timestamp":1762842051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220301301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":52,"alternative-id":["S2468294220301301"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100295","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart rate variability and vibration perception threshold to assess chemotherapy-induced neuropathy in women with breast cancer \u2013 a systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100295"}}